Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

770.79
-13.4900-1.72%
Pre-market: 771.000.2100+0.03%05:29 EST
Volume:772.71K
Turnover:592.51M
Market Cap:81.49B
PE:18.53
High:784.50
Open:784.28
Low:753.79
Close:784.28
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:1.28
T/O Rate:0.75%
Dividend:3.52
Dividend Rate:0.46%
EPS(TTM):41.59
EPS(LYR):41.48
ROE:14.87%
ROA:5.91%
PB:2.61
PE(LYR):18.58

Loading ...

EMA committee backs EU approval of Regeneron and Sanofi’s Dupixent for chronic spontaneous urticaria in children 2-11

Reuters
·
30 mins ago

Regeneron Pharmaceuticals Inc - Final Decision Expected in Coming Months

THOMSON REUTERS
·
30 mins ago

Regeneron Pharmaceuticals Inc - Chmp Recommendation Covers Children Aged 2-11 With Moderate-to-Severe Csu

THOMSON REUTERS
·
30 mins ago

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

GlobeNewswire
·
30 mins ago

Ema's Chmp: Committee Recommended to Extend Use of Dupixent (Dupilumab), for Treatment of Chronic Spontaneous Urticaria in Children Aged 2 to 11 Yrs

THOMSON REUTERS
·
1 hour ago

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

GlobeNewswire
·
19 hours ago

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Feb 25

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

TIPRANKS
·
Feb 24

FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older

Reuters
·
Feb 24

Sanofi - Phase 3 Study Shows Dupixent Reduces Nasal Signs and Symptoms

THOMSON REUTERS
·
Feb 24

Sanofi - Approval Expands Our Approved Indications in Sino-Nasal Diseases to NOW Include Afrs, Alongside Chronic Rhinosinusitis With Nasal Polyps

THOMSON REUTERS
·
Feb 24

Press Release: Sanofi and Regeneron’s Dupixent Approved in the US as the First and Only Medicine for Allergic Fungal Rhinosinusitis

THOMSON REUTERS
·
Feb 24

Regeneron Director Huda Y. Zoghbi Disposes of Common Shares

Reuters
·
Feb 24

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating

MT Newswires Live
·
Feb 20

Garetosmab Biologics License Application Accepted For FDA Priority Review

Reuters
·
Feb 19

FDA accepts Regeneron’s garetosmab BLA for priority review in FOP

Reuters
·
Feb 19

Regeneron Pharmaceuticals Inc - FDA Decision Expected by August 2026

THOMSON REUTERS
·
Feb 19

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

GlobeNewswire
·
Feb 19

Citi Reaffirms Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Feb 19